Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors

Abstract

TP53 comutation is related to poor prognosis of non-small cell lung cancer. However, there is limited study focusing on the structural influence of TP53 mutation on third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. We retrospectively analyzed the clinical and molecular data of patients treated with third-generation EGFR-TKIs in two independent cohorts. A total of 117 patients from the Sun Yat-sen University Cancer Center (SYSUCC) and 141 patients from the American Association for Cancer Research Project GENIE database were included. In the SYSUCC cohort, TP53 comutations were found in 59 patients (50.4%) and were associated with poor median progress-free survival (mPFS) and median overall survival (mOS). The additional subtype analysis found that TP53 mutation in the alpha-helix region had shorter mOS compared with those with TP53 mutations in other regions in the SYSUCC cohort (mOS, 12.2 vs. 21.7 months; p = 0.027). Similar findings were confirmed in the GENIE cohort. Specifically, the presence of TP53 mutation in the alpha-helix region was an independent negative predictive factor for PFS [hazard ratio (HR) 2.05(1.01–4.18), p = 0.048] and OS [HR 3.62(1.60–8.17), p = 0.002] in the SYSUCC cohort. TP53 mutation in alpha-helix region was related to inferior clinical outcomes in patients treated with third-generation EGFR-TKIs.

Keywords

non-small-cell lung cancer / targeted therapy / third-generation EGFR tyrosine kinase inhibitors / TP53 comutation

References

1	JC Soria, Y Ohe, J Vansteenkiste, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. doi:
2	S Zhao, Z Zhang, J Zhan, et al. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med. 2021;19(1):223. doi:
3	HA Yu, ME Arcila, N Rekhtman, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240-2247. doi:
4	TS Mok, YL Wu, MJ Ahn, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629-640. doi:
5	S Lu, X Dong, H Jian, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022;40(27):3162-3171. doi:
6	Q Zhou, L Wu, P Hu, et al. A novel third-generation EGFR tyrosine kinase inhibitor abivertinib for EGFR T790M-mutant non-small cell lung cancer: a multicenter phase I/II study. Clin Cancer Res. 2022;28(6):1127-1135. doi:
7	J Wang, B Wang, H Chu, Y Yao. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. OncoTargets Ther. 2016;9:3711-3726. doi:
8	MA Molina-Vila, J Bertran-Alamillo, A Gasco, et al. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2014;20(17):4647-4659. doi:
9	Y Jin, X Shi, J Zhao, et al. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. Lung Cancer. 2018;124:110-116. doi:
10	S Liu, J Yu, H Zhang, J Liu. TP53 co-mutations in advanced EGFR-mutated non-small cell lung cancer: prognosis and therapeutic strategy for cancer therapy. Front Oncol. 2022;12:860563. doi:
11	H Hou, K Qin, Y Liang, et al. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag Res. 2019;11:5665-5675. doi:
12	P Christopoulos, M Kirchner, J Roeper, et al. Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer. 2020;148:105-112. doi:
13	HA Yu, K Suzawa, E Jordan, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res. 2018;24(13):3108-3118. doi:
14	Y Cheng, L Ma, Y Liu, et al. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors. Lung Cancer. 2020;145:63-70. doi:
15	J Roeper, P Christopoulos, M Falk, et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res. 2022;11(1):4-13. doi:
16	M Canale, E Petracci, A Delmonte, et al. Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs. J Clin Med. 2020;9(4). doi:
17	Y Kim, B Lee, JH Shim, et al. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC. J Thorac Oncol. 2019;14(2):193-202. doi:
18	H Song, J Wu, Y Tang, et al. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med. 2023;15(690):eabn9155. doi:
19	S Chen, JL Wu, Y Liang, et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell. 2021;39(2):225-239. doi: e8
20	M Canale, E Petracci, A Delmonte, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res. 2017;23(9):2195-2202. doi:
21	ML Poeta, J Manola, MA Goldwasser, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552-2561. doi:
22	O Hassin, NB Nataraj, M Shreberk-Shaked, et al. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nat Commun. 2022;13(1):2800. doi:
23	J Roeper, M Falk, A Chalaris-Ri?mann, et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: a strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget. 2020;11(3):250-264. doi:
24	L Pauling, RB Corey, HR Branson. The structure of proteins; two hydrogen-bonded helical configurations of the polypeptide chain. Proc Nat Acad Sci USA. 1951;37(4):205-211. doi:
25	H Wang, M Guo, H Wei, Y Chen. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transd Target Ther. 2023;8(1):92. doi:
26	DB Costa. TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer. Ann Oncol. 2018;29(10):2028-2030. doi:
27	M Canale, E Petracci, P Cravero, et al. Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations. Transl Oncol. 2022;23:101471. doi:
28	N Frost, P Christopoulos, D Kauffmann-Guerrero, et al. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Therap Adv Med Oncol. 2021;13:1758835920980558. doi:
29	ER Kastenhuber, SW Lowe. Putting p53 in context. Cell. 2017;170(6):1062-1078. doi:
30	P Stockhammer, M Grant, A Wurtz, et al. Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. J Thorac Oncol. 2023. doi:
31	CMJ Steendam, GDM Veerman, MA Pruis, et al. Plasma predictive features in treating EGFR-mutated non-small cell lung cancer. Cancers. 2020;12(11). doi:
32	GJ Yang, J Li, HY Xu, et al. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. Lung Cancer. 2021;152:39-48. doi:
33	R Yu, H Bai, T Li, et al. TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. Transl Oncol. 2021;14(9):101163. doi:
34	C Murre, PS McCaw, H Vaessin, et al. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell. 1989;58(3):537-544. doi:
35	PS Freemont. The RING finger. A novel protein sequence motif related to the zinc finger. Ann NY Acad Sci. 1993;684:174-192. doi:
36	WH Landschulz, PF Johnson, SL McKnight. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science. 1988;240(4860):1759-1764. doi:
37	CN Pace, JM Scholtz. A helix propensity scale based on experimental studies of peptides and proteins. Biophys J. 1998;75(1):422-427. doi:
38	Y Zhang, J Sheng, S Kang, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One. 2014;9(9):e107161. doi:
39	W Hong, Q Wu, J Zhang, Y Zhou. Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer. Oncol Lett. 2019;18(4):3887-3895. doi:
40	D Chakravarty, J Gao, SM Phillips, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017. doi: 2017
41	T Soussi, B Leroy, PE Taschner. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. Hum Mutat. 2014;35(6):766-778. doi:
42	B Leroy, M Anderson, T Soussi. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672-688. doi:
43	B Leroy, JL Fournier, C Ishioka, et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013;41:D962-969. doi:. Database issue.
44	B Leroy, ML Ballinger, F Baran-Marszak, et al. Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice. Cancer Res. 2017;77(6):1250-1260. doi:
45	AACR Project GENIE. Powering precision medicine through an international consortium. Cancer Discov. 2017;7(8):818-831. doi: